These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1190 related articles for article (PubMed ID: 24678979)
1. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. Blom DJ; Hala T; Bolognese M; Lillestol MJ; Toth PD; Burgess L; Ceska R; Roth E; Koren MJ; Ballantyne CM; Monsalvo ML; Tsirtsonis K; Kim JB; Scott R; Wasserman SM; Stein EA; N Engl J Med; 2014 May; 370(19):1809-19. PubMed ID: 24678979 [TBL] [Abstract][Full Text] [Related]
2. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. Roth EM; McKenney JM; Hanotin C; Asset G; Stein EA N Engl J Med; 2012 Nov; 367(20):1891-900. PubMed ID: 23113833 [TBL] [Abstract][Full Text] [Related]
3. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602 [TBL] [Abstract][Full Text] [Related]
4. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R; JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642 [TBL] [Abstract][Full Text] [Related]
5. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. Stein EA; Mellis S; Yancopoulos GD; Stahl N; Logan D; Smith WB; Lisbon E; Gutierrez M; Webb C; Wu R; Du Y; Kranz T; Gasparino E; Swergold GD N Engl J Med; 2012 Mar; 366(12):1108-18. PubMed ID: 22435370 [TBL] [Abstract][Full Text] [Related]
6. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922 [TBL] [Abstract][Full Text] [Related]
8. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA; Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520 [TBL] [Abstract][Full Text] [Related]
11. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. Stroes E; Colquhoun D; Sullivan D; Civeira F; Rosenson RS; Watts GF; Bruckert E; Cho L; Dent R; Knusel B; Xue A; Scott R; Wasserman SM; Rocco M; J Am Coll Cardiol; 2014 Jun; 63(23):2541-2548. PubMed ID: 24694531 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Stein EA; Giugliano RP; Koren MJ; Raal FJ; Roth EM; Weiss R; Sullivan D; Wasserman SM; Somaratne R; Kim JB; Yang J; Liu T; Albizem M; Scott R; Sabatine MS; Eur Heart J; 2014 Sep; 35(33):2249-59. PubMed ID: 24598985 [TBL] [Abstract][Full Text] [Related]
13. Evolocumab: A Review in Hyperlipidemia. Keating GM Am J Cardiovasc Drugs; 2016 Feb; 16(1):67-78. PubMed ID: 26643308 [TBL] [Abstract][Full Text] [Related]
14. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. Sabatine MS; Giugliano RP; Keech AC; Honarpour N; Wiviott SD; Murphy SA; Kuder JF; Wang H; Liu T; Wasserman SM; Sever PS; Pedersen TR; N Engl J Med; 2017 May; 376(18):1713-1722. PubMed ID: 28304224 [TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Giugliano RP; Desai NR; Kohli P; Rogers WJ; Somaratne R; Huang F; Liu T; Mohanavelu S; Hoffman EB; McDonald ST; Abrahamsen TE; Wasserman SM; Scott R; Sabatine MS; Lancet; 2012 Dec; 380(9858):2007-17. PubMed ID: 23141813 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA; JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291 [TBL] [Abstract][Full Text] [Related]
18. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E Clin Cardiol; 2014 Mar; 37(3):131-9. PubMed ID: 24477778 [TBL] [Abstract][Full Text] [Related]
19. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333 [TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Koren MJ; Scott R; Kim JB; Knusel B; Liu T; Lei L; Bolognese M; Wasserman SM Lancet; 2012 Dec; 380(9858):1995-2006. PubMed ID: 23141812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]